Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. For all subjects, PSMA ADC will be administered in four repeating cycles.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
A diagnosis of progressive, castration-resistant, metastatic prostate cancer.
Prior chemotherapy regimens, one of which contains taxane.
Eastern Cooperative Oncology Group status of 0 or 1
Clinically significant cardiac disease or severe debilitation pulmonary disease
Evidence of an active infection requiring ongoing antibiotic therapy
Any prior treatment with any other therapy targeting PSMA